Two Sigma Securities’s Damora Therapeutics DMRA Stock Holding History

Two Sigma Securities’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,085	Closed	-$12.9K	–	3152
2024 Q2	$12.9K	Buy	+1,085	New	+$17.1K	﹤0.01%	2776
2024 Q1	–	Sell	-3,877	Closed	-$69.8K	–	3194
2023 Q4	$69.8K	Buy	+3,877	New	+$59.6K	﹤0.01%	2564

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Two Sigma Securities's DMRA Position: Q3 2024 in Review

Two Sigma Securities sold out of Damora Therapeutics (DMRA) in Q3 2024, closing a stake of 1,085 shares — an estimated $12.9K sold.

Two Sigma Securities first reported a position in DMRA in Q4 2023 and held it in 2 quarters. The position peaked at $69.8K in Q4 2023. 10 funds tracked by Wall St. Rank hold DMRA as of Q3 2024.

Two Sigma Securities reported no remaining Damora Therapeutics position as of Q3 2024 after selling out during the quarter.
Two Sigma Securities sold 1,085 Damora Therapeutics shares in Q3 2024, an estimated $12.9K.
Two Sigma Securities first reported a position in Damora Therapeutics in Q4 2023 and held it in 2 quarters.
Two Sigma Securities's Damora Therapeutics position peaked at $69.8K in Q4 2023.
10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.